[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DOP2023000088A - Derivados de pirazol como inhibidores de la ret-cinasa - Google Patents

Derivados de pirazol como inhibidores de la ret-cinasa

Info

Publication number
DOP2023000088A
DOP2023000088A DO2023000088A DO2023000088A DOP2023000088A DO P2023000088 A DOP2023000088 A DO P2023000088A DO 2023000088 A DO2023000088 A DO 2023000088A DO 2023000088 A DO2023000088 A DO 2023000088A DO P2023000088 A DOP2023000088 A DO P2023000088A
Authority
DO
Dominican Republic
Prior art keywords
ret
kinase
inhibitors
pyrazole derivatives
compounds
Prior art date
Application number
DO2023000088A
Other languages
English (en)
Inventor
W Andrews Steven
R Condroski Kevin
D Anderson Erin
Pierre Albert Jean Boldron Christopher
C Irvin Thomas
Kumar Manoj
A Mcfaddin Elizabeth
L Mckenney Megan
Mouret Tiphaine
J Munchhof Michael
Pierre Dino Pancaldi Thomas
Alexander Pilkington-Mikas Michael
PINTO Marta
Alexander Mclean Johnathan
R A/K/A Jody Gabrielle Rustmann Kolakowski Kolakowski Gabrielle
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2023000088A publication Critical patent/DOP2023000088A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

En la presente descripción se describen compuestos de Fórmula I: o una sal farmacéuticamente aceptable de este, donde las variables son como se definen en la presente descripción. Estos compuestos son útiles en el tratamiento de cánceres asociados a RET. También se describen formulaciones que contienen los compuestos de Fórmula I y métodos para preparar los compuestos de Fórmula I.
DO2023000088A 2020-11-06 2023-05-05 Derivados de pirazol como inhibidores de la ret-cinasa DOP2023000088A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063110643P 2020-11-06 2020-11-06
PCT/US2021/058206 WO2022098970A1 (en) 2020-11-06 2021-11-05 Pyrazole derivatives asr et kinase inhibitors

Publications (1)

Publication Number Publication Date
DOP2023000088A true DOP2023000088A (es) 2023-07-16

Family

ID=78806726

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2023000088A DOP2023000088A (es) 2020-11-06 2023-05-05 Derivados de pirazol como inhibidores de la ret-cinasa

Country Status (18)

Country Link
US (2) US11697647B2 (es)
EP (1) EP4240738A1 (es)
JP (2) JP7338072B2 (es)
KR (1) KR20230104146A (es)
CN (1) CN116438179A (es)
AR (1) AR124007A1 (es)
AU (1) AU2021376367B2 (es)
CA (1) CA3197032A1 (es)
CL (1) CL2023001277A1 (es)
CO (1) CO2023005600A2 (es)
CR (1) CR20230193A (es)
DO (1) DOP2023000088A (es)
EC (1) ECSP23033180A (es)
IL (1) IL302542A (es)
MX (1) MX2023005289A (es)
PE (1) PE20231984A1 (es)
TW (2) TW202315623A (es)
WO (1) WO2022098970A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11697647B2 (en) * 2020-11-06 2023-07-11 Eli Lilly And Company RET kinase inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2970191T3 (pl) 2013-03-15 2017-07-31 Glaxosmithkline Intellectual Property Development Limited Pochodne pirydyny jako inhibitory kinazy przebudowanej podczas transfekcji (RET)
WO2017145050A1 (en) 2016-02-23 2017-08-31 Glaxosmithkline Intellectual Property Development Limited Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer
WO2017161269A1 (en) 2016-03-17 2017-09-21 Blueprint Medicines Corporation Inhibitors of ret receptor tyrosine kinases
CN112566907A (zh) 2018-08-17 2021-03-26 南京明德新药研发有限公司 作为ret抑制剂的吡唑衍生物
AR121914A1 (es) 2020-04-27 2022-07-20 Lilly Co Eli Compuestos útiles para inhibir la quinasa ret
US11697647B2 (en) * 2020-11-06 2023-07-11 Eli Lilly And Company RET kinase inhibitors

Also Published As

Publication number Publication date
US20230265085A1 (en) 2023-08-24
CR20230193A (es) 2023-07-03
US11697647B2 (en) 2023-07-11
KR20230104146A (ko) 2023-07-07
JP2023504303A (ja) 2023-02-02
CL2023001277A1 (es) 2023-12-01
AR124007A1 (es) 2023-02-01
JP7338072B2 (ja) 2023-09-04
AU2021376367A9 (en) 2023-07-13
TW202315623A (zh) 2023-04-16
WO2022098970A9 (en) 2023-04-27
IL302542A (en) 2023-07-01
WO2022098970A1 (en) 2022-05-12
CN116438179A (zh) 2023-07-14
CA3197032A1 (en) 2022-05-12
ECSP23033180A (es) 2023-06-30
CO2023005600A2 (es) 2023-05-29
TWI790810B (zh) 2023-01-21
EP4240738A1 (en) 2023-09-13
JP2023099116A (ja) 2023-07-11
US20220144816A1 (en) 2022-05-12
AU2021376367A1 (en) 2023-05-11
PE20231984A1 (es) 2023-12-12
US11970485B2 (en) 2024-04-30
MX2023005289A (es) 2023-07-26
AU2021376367B2 (en) 2024-08-01
TW202233180A (zh) 2022-09-01

Similar Documents

Publication Publication Date Title
ECSP21091615A (es) Derivados de benzisoxazol sulfonamida
CL2020002748A1 (es) Inhibidores de cinasa dependientes de ciclina
CL2019000368A1 (es) Inhibidores de cdk2/4/6.
CO2022006858A2 (es) Inhibidores de pequeñas moléculas de mutante g12c de kras
UY37900A (es) Nuevos derivados de rapamicina
CL2017002207A1 (es) Inhibidores del factor beta de crecimiento de transformación (tgf-beta)
ECSP21034668A (es) Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento de cáncer
CO2021003115A2 (es) Inhibidores de sarcómeros cardíacos
CO2023001668A2 (es) Derivados de 1h-benzo[d]imidazol como inhibidores de tlr9 para el tratamiento de fibrosis
ECSP23045506A (es) DERIVADOS DE INDOL ÚTILES EN EL TRATAMIENTO DE AFECCIONES ASOCIADAS CON cGAS
CO2020010306A2 (es) Compuestos de sulfonimidoilpurinona 7-sustituida y derivados para el tratamiento y profilaxis de cáncer de hígado.
AR128500A1 (es) Inhibidores de arn helicasa dhx9 y usos de los mismos
CL2022002975A1 (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
DOP2023000088A (es) Derivados de pirazol como inhibidores de la ret-cinasa
CL2019001023A1 (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia.
ECSP16083017A (es) Derivados de diheterociclo enlazado a cicloalquilo
CO2023012702A2 (es) Derivados de diazepina útiles en el tratamiento de clostridium difficile
CO2021004873A2 (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
PE20211454A1 (es) Derivados de imidazopiridina y su uso como medicamento
AR125479A1 (es) Inhibidores de il4i1 y métodos de uso
CO2024012743A2 (es) Derivados de 6-oxodecahidropirrolo[1,2-a][1,5]diazocina y 6-oxodecahidro-4h-pirrolo[2,1-d][1,5]tiazocina como moduladores de stat3 y stat6 para el tratamiento de cáncer y condiciones inflamatorias
DOP2024000096A (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno